CAH · NYQ · Healthcare
Cardinal Health, Inc.
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 173.89
Market price
USD 225.38
Implied upside
-22.8%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY27 | FY28 | FY29 | FY30 | FY31 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 273.2bn | USD 293.5bn | USD 315.4bn | USD 338.8bn | USD 364.1bn | +7.4% |
| EBIT | USD 2.8bn | USD 3.0bn | USD 3.2bn | USD 3.5bn | USD 3.7bn | +7.4% |
| NOPAT | USD 2.2bn | USD 2.4bn | USD 2.6bn | USD 2.7bn | USD 3.0bn | +7.4% |
| Add depreciation & amortisation | USD 943.5m | USD 1.0bn | USD 1.1bn | USD 1.2bn | USD 1.3bn | +7.4% |
| Less capital expenditure | USD -2.7bn | USD -2.9bn | USD -3.2bn | USD -3.4bn | USD -3.6bn | +7.4% |
| Less increase in working capital | USD 1.3bn | USD 1.4bn | USD 1.5bn | USD 1.6bn | USD 1.7bn | -7.4% |
| Free cashflow to firm | USD 1.7bn | USD 1.9bn | USD 2.0bn | USD 2.2bn | USD 2.3bn | +7.4% |
| Discount factor | 0.9621 | 0.8906 | 0.8243 | 0.7630 | 0.7063 | - |
| Present value | USD 1.7bn | USD 1.7bn | USD 1.6bn | USD 1.6bn | USD 1.6bn | -0.5% |
| Present Value Of The Forecast | USD 8.2bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.678 | Reported 0.519, pulled toward 1.0 (Blume) |
| Cost of equity | 8.73% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.00% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 52.4bn | 85.5% of capital |
| Total debt | USD 8.9bn | 14.5% of capital, book value as a proxy |
| Tax rate | 21.0% | Effective, capped at statutory |
| WACC | 8.03% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
82% of EV
- Forecast FCFF, final year
- USD 2.3bn
- Capex at depreciation, working capital in reinvestment
- USD 3.0bn
- Less reinvestment at g/ROIC (4.2% of NOPAT)
- USD -122.9m
- Capitalised
- USD 2.8bn
- ROIC (reported)
- 60.0%
- Terminal value, undiscounted
- USD 52.4bn
- Terminal value, discounted
- USD 37.0bn
- Enterprise value
- USD 45.2bn
- Less net debt
- USD 4.0bn
- Equity value
- USD 41.2bn
Exit at 13.7x EBITDA
85% of EV
- Terminal value, undiscounted
- USD 68.2bn
- Terminal value, discounted
- USD 48.2bn
- Enterprise value
- USD 56.4bn
- Less net debt
- USD 4.0bn
- Equity value
- USD 52.4bn
Spread between methods: 24%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 6.03% | 228.25 | 253.27 | 285.36 | 327.99 | 387.42 |
| 7.03% | 182.59 | 198.22 | 217.28 | 241.04 | 271.52 |
| 8.03% | 150.98 | 161.49 | 173.89 | 188.73 | 206.83 |
| 9.03% | 127.82 | 135.27 | 143.84 | 153.82 | 165.59 |
| 10.03% | 110.15 | 115.62 | 121.82 | 128.89 | 137.03 |
Outlined: this model. Green text: above today's price of 225.38. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 7.4% | 11.6% | +4.1pp |
| EBIT margin | 1.0% | 1.3% | +0.3pp |
| Discount rate | 8.0% | 6.9% | -1.1pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.